This morning, the American Civil Liberties Union, which will be represented in Wednesday’s hearing on Section 101 reform by Senior Legislative Counsel Kate Ruane, announced an urgent joint phone briefing for members of Congress and staff to address the contention that the “Proposed Patent Bill Would Jeopardize Health Care and Harm Medical Research.” The phone briefing, taking place today at 2:30 pm EST, will be jointly held by representatives from the ACLU, the Association for Molecular Pathology, a breast cancer survivor and patient, My Gene Counsel, and Invitae. Below, Sherry Knowles, former Senior Vice President and Chief Patent Counsel at GlaxoSmithKline, rebuts the arguments made in both the ACLU’s briefing announcement and associated letter to Congress on this topic.
Recent Posts
- Other Barks & Bites for Friday, June 20: Advocate General Tells CJEU to Affirm €4 Billion Antitrust Fine Against Google; Recentive Challenges Section 101 Invalidation of Machine Learning Claims
- Stewart Expands on ‘Settled Expectations’ Criteria in Interim Discretionary Denial Process
- Mediocre Results so Far for Deferred Subject Matter Eligibility Response Pilot
- European Patent Organization: Responses from ChatGPT Do Not Represent the “Understanding of a Skilled Person”
- Blackburn and Hirono Sign on to PERA 2025